好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Healthcare Resource Utilization in Adult Patients Treated With OnabotulinumtoxinA for Chronic Migraine: Results From the COMPEL Study
Headache
S8 - Migraine Therapeutics (4:42 PM-4:54 PM)
007
To evaluate healthcare resource utilization (HRU) by patients treated with onabotulinumtoxinA for chronic migraine (CM) in a subanalysis of the COMPEL study.

Population-based studies have shown that patients with CM have greater headache-related disability, increased HRU, and higher direct and indirect costs.
The single-arm, open-label COMPEL study (NCT01516892) enrolled adults with CM receiving onabotulinumtoxinA 155 U approximately every 12 weeks (9 treatments). Patients recorded headache (HA) days in a daily diary to assess mean change from baseline in the number of HA days/28-day period up to 108 weeks. HRU data, including total HA-related visits to a healthcare professional (HCP), emergency room (ER)/urgent care (UC) visits, overnight stays, and number of HA-related diagnostic tests, were collected at baseline and at each treatment session. P-values were based on t-test or Wilcoxon signed rank test.

Patients (N=716 enrolled) were, on average, aged 43 years, female (85%), with a family history of migraine (63%). At baseline, 557 patients reported a mean (SD) of 7.0 (15.4) and a minimum-maximum of 0-198 HA-related visits to an HCP. Visit frequency was significantly reduced at all time points. The majority of patients reported seeing a neurologist/HA specialist, followed by a primary care physician. At baseline, 690 patients reported a mean (SD) of 0.5 (2.0) HA-related ER/UC visits, and 691 patients reported 0.2 (1.5) HA-related overnight hospital stays. Following onabotulinumtoxinA treatment, HA-related ER/UC visits and overnight hospital stays were significantly reduced at all time points. At baseline, 193 patients reported a total of 487 HA-related diagnostic tests. A total of 334 HA-related diagnostic tests were reported from weeks 24 to 96. Commonly reported diagnostic tests at baseline included blood tests (21.0%), MRI (18.7%), and CAT/CT scans (10.9%).
Real-world findings from the COMPEL study show that onabotulinumtoxinA treatment is associated with HRU reductions.
Authors/Disclosures
John F. Rothrock, MD (Inova Health)
PRESENTER 		The institution of Dr. Rothrock has received research support from AbbVie.
Richard Stark, MBBS, FRACP Dr. Stark has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Stark has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Stark has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Stark has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Stark has stock in CSL. Dr. Stark has stock in Multiple ASX listed (non-medical) companies. Dr. Stark has received personal compensation in the range of $10,000-$49,999 for serving as a TCMC Committee chair with AMA Victoria.
Katherine Sommer Katherine Sommer has received personal compensation for serving as an employee of AbbVie. Katherine Sommer has stock in AbbVie.
Andrew M. Blumenfeld, MD, FAAN (The Los Angeles Headache Center) Dr. Blumenfeld has received personal compensation for serving as an employee of The Los Angeles Headache Center. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Allergan. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Best Doctors. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GLG. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Aeon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Revance. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Abbvie. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Axon. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Blumenfeld has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Teva. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lilly. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck.